Recilisib (ON-01210; ON 01210; ON01210; EX-RAD) is a novel and potent radioprotectant undergoing phase I clinical trials by Onconova Therapeutics for the treatment of acute radiation syndrome. It mitigates radiation damage through activation of the AKT pathway.

纯度：≥98%

CAS：334969-03-8